Skip to main content

Table 1 Characteristics of HIV-patients according to origin and stages of tuberculosis infection

From: HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2 year follow-up; a Norwegian prospective multicenter study

 

TB-endemic countries (N = 217)

TB low-endemic countries (N = 81)

 

LTBI

Prior TB*

Active TB

Prior LTBI

No TB

LTBI

Prior TB

No TB

(N = 60)

(N = 23)

(N = 7)

(N = 4)

(N = 123)

(N = 4)

(N = 3)

(N = 74)

Age

        

 Median (IQR)

37 (31–41)

41 (36–46)

43 (39–48)

45 (37–49)

36 (31–42)

44 (40–47)

50 (43–60)

53 (46–60)

Gender

        

 Female N (%)

36 (60)

11 (48)

3 (43)

2 (50)

87 (71)

2 (50)

1 (67)

19 (26)

 Male N (%)

24 (40)

12 (52)

4 (57)

2 (50)

36 (29)

2 (50)

2 (33)

55 (74)

Years of stay in Norway

        

 Median (IQR)

5 (2–8)

7 (3–11)

5 (1–6)

4 (3–5)

7 (4–10)

n/a

n/a

n/a

Years of HIV infection

        

 Median (IQR)

3 (2–7)

8 (3–10)

7 (3–10)

6 (5–8)

6 (3–9)

16 (9–20)

6 (3–23)

6 (3–11)

Nadir CD4 cells/μl

        

 Median (IQR)

270 (170–488)

80 (40–190)

190 (50–290)

92 (81–190)

188 (87–290)

135 (90–180)

101 (100–230)

192 (90–354)

CD4 cells/μl at enrolment

        

 Median (IQR)

472 (342–638)

340 (240–430)

270 (50–340)

541 (442–608)

408 (276–590)

465 (375–595)

320 (310–560)

468 (312–690)

ART at enrolment N (%)

28 (47)

17 (74)

5 (71)

4 (100)

88 (71)

4 (100)

3 (100)

49 (66)

Exposure to TB

16 (27)

1 (4)

2 (29)

2 (50)

8 (6)

0

1 (33)

6 (8)

TST positive (%)

30 (60)1

8 (47)3

1 (25)5

07

10 (10)8

010

1 (50)12

2 (5)14

TST mm (median-IQR)

10 (0–15)

3 (0–15)

0 (0–5)

0 (0–0)

0

0 (0–1)

11 (0–22)

0

QFT positive (%)

56 (93)

9 (35)

6 (86)

1 (25)

0

4 (100)

1 (33)

0

QFT IU/ml (median-IQR)

2.00 (0.56–6.20)

0.34 (0.34–1.88)

6.33 (0.81–10)

10 (10–10)

0.34

0.91 (0.49–5.63)

0.34 (0.34–10)

0.34

TSPOT positive (%)

20 (87)2

6 (50)4

3 (60)6

….

09

011

013

015

TST/QFT discordance N (%)

22 (44)

5 (29)

2 (50)

0

10 (10)

3 (60)

0

2 (5)

 TST-/QFT+

19

2

2

0

0

3

0

0

 TST+/QFT-

3

3

0

0

10

0

0

2

  1. TB: tuberculosis. LTBI: latent TB infection. ART: antiretroviral therapy. QFT: QuantiFERON TB Gold. TSPOT: T-SPOT.TB. n/a: not applicable. *Excludes 2 diagnosed with LTBI and 4 diagnosed with current active TB. 1TST available in 50 LTBI pasients from TB-endemic countries. 2TSPOT available in 23 LTBI pasients from TB-endemic countries. 3TST available in 17 patients with prior TB from TB-endemic countries. 4TSPOT available in 12 patients with prior TB from TB-endemic countries. 5 TST results available in 4 patients with active TB. 6 TSPOT results available in 5 patients with active TB. 7TST results available in 2 patients with prior LTBI. 8 TST available in 96 “no TB” patients from TB-endemic countries. 9TSPOT available in 44 “no TB” patients from TB-endemic countries. 10TST available in 3 LTBI pasients from TB low-endemic countries. 11TSPOT available in 2 LTBI pasients from TB low-endemic countries. 12TST available in 2 patients with prior TB from TB low-endemic countries. 13 TSPOT available in 2 patients with prior TB from TB low-endemic countries. 14TST available in 43 “no TB” patients from TB low-endemic countries. 15TSPOT available in 28 “no TB” patients from TB low-endemic countries.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us